Here, we demonstrated that when expressed in p16-null pancreatic cancer cells, p16-L16R had little ability to suppress the cell cycle and exhibited decreased binding to CDK4 and CDK6 compared with p16-WT. This evidence concerns the gene CDKN2A and pancreatic neoplasm.